Greenwich LifeSciences reports progress in FLAMINGO-01 trial
STAFFORD, Texas - Greenwich LifeSciences, Inc. (NASDAQ:GLSI), a clinical-stage biopharmaceutical company valued at $163 million, has announced the commencement of analysis on the open label HLA data ...
Nasdaq1 个月
Greenwich LifeSciences Collaborates With German Breast Group To Accelerate FLAMINGO-01 Trial
an academic breast cancer research network, to expand its Phase III clinical trial, dubbed FLAMINGO-01, in Germany. The FLAMINGO-01 phase III trial is designed to assess the safety and efficacy of ...
来自MSN1 个月
EMA approves addition of sites to Greenwich LifeSciences’ breast cancer trial
The European Medicines Agency (EMA) has approved the expansion of Greenwich LifeSciences’ Phase III FLAMINGO-01 breast cancer trial in Europe to add 11 new sites across Germany, Poland ...
Business Insider1 个月
Greenwich LifeSciences Partners with Unicancer Expanding Flamingo-01 into France
STAFFORD, Texas, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial ...
Business Insider1 个月
Greenwich LifeSciences partners with Unicancer expanding Flamingo-01 into France
The Company has partnered with Unicancer and its breast cancer group. The FLAMINGO-01 study will be activated in approximately 19 French sites in the UCBG network. These sites were approved by ...